Discovery of a novel 1H-pyrazole- [3,4-b] pyridine-based lysine demethylase 5B inhibitor with potential anti-prostate cancer activity that perturbs the phosphoinositide 3-kinase/AKT pathway
作者:Yaquan Cao、Pu Yang、Yingxue Yang、Zihui Lin、Zhengmin Fan、Xuliang Wei、Lijie Yan、Yongchun Li、Zhangxu He、Liying Ma、Hongde Xu、Chunli Wu
DOI:10.1016/j.ejmech.2023.115250
日期:2023.5
Lysine demethylase 5B (KDM5B) is a member of the Jumonji AT-rich interactive domain 1 family. Its main function is to demethylate di/trimethyl histone H3 lysine 4 and it plays a crucial role in the occurrence and development of cancer. In this study, we performed structure-based optimization of KDM5B inhibitors based on our previous work and the most active compound we synthesized was 11ad. Molecular
赖氨酸脱甲基酶 5B (KDM5B) 是 Jumonji AT-rich interactive domain 1 家族的成员。其主要功能是使二/三甲基组蛋白H3赖氨酸4去甲基化,在癌症的发生发展中起着至关重要的作用。在这项研究中,我们根据之前的工作对 KDM5B 抑制剂进行了基于结构的优化,我们合成的活性最高的化合物是11ad。分子建模研究和热位移分析表明,11ad在分子和细胞水平上特异性靶向 KDM5B。至关重要的是,11ad在异种移植模型中表现出良好的药代动力学特性和抗前列腺癌活性。此外,出乎意料的是, 11ad的特异性发现前列腺癌与其抑制磷酸肌醇 3-激酶/AKT 通路有关。这是影响该通路的 KDM5B 抑制剂的第一份报告。总之,我们的研究结果表明11ad是一种新型 KDM5B 抑制剂,可作为开发前列腺癌治疗方法的先导化合物。